Hetero Labs Gets CDSCO Panel Nod to Study Vonoprazan Tablet

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2024-11-01 12:00 GMT | Update On 2024-11-01 12:00 GMT

New Delhi: Hetero Labs has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase IV clinical trial of Vonoprazan, a potassium-competitive acid blocker used in the treatment of acid-related disorders and as an adjunct to Helicobacter pylori eradication.

This came after the firm presented the proposal for a grant of permission to conduct a phase IV clinical trial with the new drug Vonoprazan 20 mg tablets before the committee.

Vonoprazan is a potassium-competitive acid blocker (PCAB) that inhibits H+, K+-ATPase-mediated gastric acid secretion. PCABs represent an alternative to proton-pump inhibitors for the treatment of acid-related disorders.

Vonoprazan is used to heal and maintain healing of erosive esophagitis (inflammation that causes damage to the tube that runs from the throat to the stomach) and helps lessen symptoms of heartburn associated with erosive esophagitis in adults.

At the recent SEC meeting for gastroenterology and hematology held on October 16, 2024, the expert panel reviewed the proposal for the grant of permission to conduct a phase IV clinical trial with the new drug Vonoprazan 20 mg tablets.

After detailed deliberation, the committee recommended the grant of permission to conduct a Phase IV clinical trial as per the presented protocol.

Also Read: Sanofi gets CDSCO Panel nod to study Amlitelimab

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Hetero Labs Gets CDSCO Panel Nod to Study Vonoprazan Tablet

Similar News

CDSCO Tightens RTI Appeal Timelines, Division Heads to Face Penalties for Lapses

Patna HC Denies Bail in Codeine Syrup Case: Possession Below 2.5% Still NDPS Offence

Alembic Pharma Gets USFDA Nod for Generic Paxil CR Tablets

Game-Changer for HIV: Dr Reddy's, Hetero to Sell Generic Lenacapavir at Rs 3,547 a Year

Sanofi Commits USD 625 Million to Sanofi Ventures to Boost Biotech and Digital Health Startups

Syneos Health Asked to Clarify Phase II Tacrolimus Trial Protocol by CDSCO Panel

Zydus Lifesciences Gets CDSCO Panel Nod for Bioavailability Study of Antimalarial Candidate ZY-19489

Serum Institute, Vidal Health Partner for Digital Cashless HPV Vaccination Programme